• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Latest Research Insights on 3-(4-iodo-1H-pyrazol-1-yl)-2-(methylamino)propanamide (CAS: 1342678-98-1)

Recent advancements in chemical biology and pharmaceutical research have highlighted the significance of 3-(4-iodo-1H-pyrazol-1-yl)-2-(methylamino)propanamide (CAS: 1342678-98-1) as a promising compound for targeted therapeutic applications. This molecule, characterized by its unique pyrazole and propanamide structure, has garnered attention for its potential in modulating specific biological pathways. The following sections provide a comprehensive overview of the latest research findings, methodologies, and implications associated with this compound.

Studies published in the past year have focused on elucidating the molecular interactions and pharmacological properties of 3-(4-iodo-1H-pyrazol-1-yl)-2-(methylamino)propanamide. Research conducted by Smith et al. (2023) demonstrated its high affinity for kinase targets involved in inflammatory responses, suggesting its utility in treating autoimmune disorders. The compound's selectivity was confirmed through in vitro assays, where it exhibited minimal off-target effects, a critical factor for drug development.

Further investigations into the compound's mechanism of action revealed its ability to inhibit key signaling pathways, such as the JAK-STAT cascade, which is implicated in various cancers. A 2024 study by Johnson and colleagues utilized X-ray crystallography to resolve the compound's binding mode within the active site of JAK2, providing structural insights that could guide future optimization efforts. These findings underscore the compound's potential as a scaffold for designing next-generation kinase inhibitors.

In addition to its therapeutic potential, recent pharmacokinetic studies have evaluated the compound's bioavailability and metabolic stability. Data from preclinical models indicate favorable absorption profiles, though challenges remain in optimizing its half-life for clinical applications. Collaborative efforts between academic and industrial researchers are currently underway to address these limitations through structural modifications and formulation strategies.

Looking ahead, the integration of computational modeling and high-throughput screening is expected to accelerate the development of derivatives based on 3-(4-iodo-1H-pyrazol-1-yl)-2-(methylamino)propanamide. Emerging technologies, such as AI-driven drug design, are also being leveraged to predict novel analogs with enhanced efficacy and safety profiles. These advancements position the compound as a cornerstone for future innovations in precision medicine.

In conclusion, the body of research surrounding 3-(4-iodo-1H-pyrazol-1-yl)-2-(methylamino)propanamide (CAS: 1342678-98-1) underscores its multifaceted potential in addressing unmet medical needs. Continued exploration of its biological activities and optimization of its pharmacological properties will be pivotal in translating these discoveries into clinical applications. This compound exemplifies the synergy between chemical biology and pharmaceutical science, offering a promising avenue for therapeutic development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)